{"url":"https://newsforagent.com/news/2026-11-22/nurix-therapeutics-sbs-law-investigation","markdown_url":"https://newsforagent.com/news/2026-11-22/nurix-therapeutics-sbs-law-investigation.md","title":"Nurix Therapeutics Faces SBS Law Probe","headline":"Nurix Therapeutics Investigated by SBS Law After Sanofi Ends SAR448272 Trial","description":"Schall, Brown & Schwartz is investigating Nurix Therapeutics over statements tied to Sanofi's halt of the SAR448272 trial.","section":"Legal & Disputes","published_at":"2026-11-22T00:35:56+00:00","modified_at":"2026-11-22T00:35:56+00:00","author":"News Desk","key_takeaways":["Schall, Brown & Schwartz LLP is investigating Nurix Therapeutics for possible securities law violations.","Sanofi decided on November 3, 2026, to discontinue the Phase 1 trial of SAR448272 and terminate development of the drug.","Nurix shares fell more than 38.2% the day after the Sanofi decision was disclosed."],"companies":[{"name":"Nurix Therapeutics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000mri/nurix-therapeutics","website":"https://www.nurixtx.com"}],"source":{"publisher":"Business Wire","title":"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law","url":"https://www.businesswire.com/news/home/20261121449424/en/"},"other_sources":[{"publisher":"The future of trading","url":"https://capital.com/en-int/news/amd-investors-have-opportunity-to-join-advanced-micro-devices-inc"}],"tags":["Legal & Disputes","Nurix Therapeutics"],"body_markdown":"Schall, Brown & Schwartz LLP is investigating [Nurix Therapeutics](https://akta.pro/company-profiles/0000mri/nurix-therapeutics) for possible violations of securities laws, the firm said in a [Business Wire release](https://www.businesswire.com/news/home/20261121449424/en/). The investigation concerns whether Nurix issued false or misleading statements or withheld information from investors, according to the announcement.\n\n## What the SBS Law Investigation Covers\n\nThe firm said its inquiry centers on Nurix's disclosures to investors. Nurix revealed on November 3, 2026, that Sanofi decided to discontinue the Phase 1 trial of SAR448272, an investigational drug for inflammatory diseases, and to terminate development of the drug altogether, according to the release. Shares of Nurix fell by more than 38.2% on the next day, the firm said.\n\nSBS Law is a national shareholder rights litigation firm. The release names Brian Schall, Andrew Brown and David Schwartz as founding partners and invites shareholders who suffered a loss to contact the firm.\n\nSBS Law has also announced an investigation into Advanced Micro Devices for potential securities law violations, [The future of trading](https://capital.com/en-int/news/amd-investors-have-opportunity-to-join-advanced-micro-devices-inc) reported on November 20, 2026. That inquiry cites a Hunterbrook report alleging AMD issued false statements and bills over 20% of revenue to China and Hong Kong, and AMD shares fell more than 7.7% the same day, according to the outlet.\n\n## Nurix's Pipeline and Financing Record\n\nNurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for hematologic cancers, solid tumors and autoimmune diseases, according to akta.pro [company records](https://akta.pro/company-data). The same records show a June 2026 global co-development and co-commercialization collaboration with Roche for bexobrutideg, including $700 million upfront and up to $2.3 billion in potential total deal value, with development costs split 60/40 in Roche's favor. Nurix priced a $250 million registered offering of approximately 24.49 million shares at $10.21 per share in October 2025, the records show.\n\n## Sanofi Program and Earlier Nurix Moves\n\nSanofi's decision to discontinue the Phase 1 trial of oral STAT6 degrader SAR448272 and terminate the program, ending potential payments tied to it, was reported by TradingView on November 3, 2026. Simply Wall St reported on November 15, 2026, that Nurix appointed Arati V. Rao as chief medical officer and that partner Sanofi ended the SAR448272 STAT6 degrader program, removing up to about US$453 million in milestones and royalties. Stock Titan reported on November 11, 2026, that Nurix appointed Arati V. Rao, M.D., as chief medical officer to lead its clinical development organization.\n\n## What Comes Next for Nurix\n\nNurix management will participate in fireside chats at the UBS Global Biopharma, Jefferies Global Healthcare and Piper Sandler Annual Healthcare conferences, Stock Titan reported on November 10, 2026. The chats are webcast live and archived for 30 days, according to the report.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}